KPW
ADPT icon

Kore Private Wealth’s Adaptive Biotechnologies ADPT Stock Holding History

Kore Private Wealth’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-10
Closed – – 285
2020
Q2 		$0 Buy
+10
New +$365 ﹤0.01% 1150

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
SIG
Senator Investment Group New York $2.18B AUM 58.56% 1-Year Est. Return

Kore Private Wealth's ADPT Position: Q3 2020 in Review

Kore Private Wealth sold out of Adaptive Biotechnologies (ADPT) in Q3 2020, closing a stake of 10 shares.

Kore Private Wealth first reported a position in ADPT in Q2 2020 and held it in 1 quarter. The position peaked at $0 in Q2 2020. 206 funds tracked by Wall St. Rank hold ADPT as of Q3 2020.

  • Kore Private Wealth reported no remaining Adaptive Biotechnologies position as of Q3 2020 after selling out during the quarter.
  • Kore Private Wealth sold 10 Adaptive Biotechnologies shares in Q3 2020.
  • Kore Private Wealth first reported a position in Adaptive Biotechnologies in Q2 2020 and held it in 1 quarter.
  • Kore Private Wealth's Adaptive Biotechnologies position peaked at $0 in Q2 2020.
  • 206 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q3 2020.

Based on Kore Private Wealth's 13F filing for Q3 2020, filed 13 Nov 2020.